Want to see HK:2137 full AI Analyst Report?

Brii Biosciences Limited (2137) Price & Analysis

3 Followers

2137 Stock Chart & Stats

HK$1.44

HK$0.04(3.74%)

At close: Jan 09 4:00 PM EST

HK$1.44

HK$0.04(3.74%)

Day’s Range― - ―

52-Week RangeHK$0.90 - HK$2.34

Previous CloseN/A

Volume2.92M

Average Volume (3M)6.36M

Market Cap

HK$693.35M

Enterprise Value-HK$1.40K

Total Cash (Recent Filing)HK$1.77B

Total Debt (Recent Filing)HK$6.18M

Price to Earnings (P/E)―

Beta1.43

Next Earnings

Mar 19, 2027

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.24

Shares Outstanding734,958,250

10 Day Avg. Volume5,897,564

30 Day Avg. Volume6,360,478

Financial Highlights & Ratios

PEG Ratio0.07

Price to Book (P/B)0.38

Price to Sales (P/S)50.44

P/FCF Ratio-3.17

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.43

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage And Positive EquityA lightly leveraged balance sheet and sizable positive equity cushion reduce financial risk and preserve flexibility to fund development, absorb setbacks, and pursue commercialization without excessive debt pressure.

Improving Losses And Cash BurnThe reduction in losses and cash burn provides evidence of some operating progress. If sustained, this could extend liquidity, lower financing needs, and improve the company’s ability to advance its pipeline.

Partner-led Commercialization ModelReliance on in-licensed and partnered assets can broaden product access while sharing development and commercialization costs with larger pharmaceutical or biotech partners, potentially improving capital efficiency.

Bears Say

Persistent Losses And Negative MarginsContinued losses and deeply negative margins show that the business has not reached sustainable profitability. This limits internally generated funding and leaves results dependent on successful products, partnerships, or further financing.

Sharp Revenue ContractionA material revenue decline weakens operating scale and suggests that commercialization momentum remains fragile. Lower revenue can reduce fixed-cost absorption and make it harder for the company to convert its pipeline into durable earnings.

Ongoing Operating Cash BurnPersistent negative operating and free cash flow means the company cannot currently fund operations from internally generated cash. Continued dependence on liquidity or external funding increases execution and financing risk over the medium term.

Brii Biosciences Limited News

Brii Biosciences Narrows Interim Loss as HBV and RNA Pipelines Advance

An announcement from Brii Biosciences Limited ( ($HK:2137) ) is now available. Brii Biosciences Limited reported unaudited interim...

10d ago

Brii Biosciences Sets August Board Meeting to Approve 2026 Interim Results

Brii Biosciences Limited ( ($HK:2137) ) just unveiled an announcement. Brii Biosciences Limited has announced that its board...

23d ago

Brii Biosciences Posts Promising Phase 2b Hepatitis B Data but Elebsiran Future Clouded by Arbitration

Brii Biosciences Limited ( ($HK:2137) ) just unveiled an announcement. Brii Biosciences has reported end-of-treatment data from its...

2M ago

Brii Biosciences Launches HK$60 Million Share Buy-back to Signal Confidence and Unlock Value

Brii Biosciences Limited ( ($HK:2137) ) has provided an announcement. Brii Biosciences Limited has announced that its board...

2M ago

Brii Biosciences Shareholders Approve All Resolutions at 2026 AGM

Brii Biosciences Limited ( ($HK:2137) ) has shared an announcement. Brii Biosciences reported that all resolutions proposed at...

3M ago

Brii Biosciences Warns Hepatitis B Drug Program at Risk Amid Vir Arbitration

Brii Biosciences Limited ( ($HK:2137) ) has provided an update. Brii Biosciences has disclosed that its ongoing arbitration...

3M ago

Brii Biosciences Data Backs Shorter NRTI Use in Next-Generation HBV Therapies

An announcement from Brii Biosciences Limited ( ($HK:2137) ) is now available. Brii Biosciences has presented new data...

4M ago

Brii Biosciences Sets 2026 AGM to Approve Accounts, Board Mandates and Share Issuance Authority

Brii Biosciences Limited ( ($HK:2137) ) has shared an update. Brii Biosciences Limited has called its annual general...

4M ago

Brii Biosciences Launches Arbitration Against Vir Over Hepatitis B Drug Manufacturing Rights

The latest announcement is out from Brii Biosciences Limited ( ($HK:2137) ). Brii Biosciences has initiated arbitration proceedings...

5M ago

Brii Biosciences Narrows 2025 Loss as Costs Fall and Revenue Emerges

An announcement from Brii Biosciences Limited ( ($HK:2137) ) is now available. Brii Biosciences reported its annual results...

5M ago

2137 FAQ

What was Brii Biosciences Limited’s price range in the past 12 months?

Brii Biosciences Limited lowest stock price was HK$0.90 and its highest was HK$2.34 in the past 12 months.

What is Brii Biosciences Limited’s market cap?

Brii Biosciences Limited’s market cap is HK$693.35M.

When is Brii Biosciences Limited’s upcoming earnings report date?

Brii Biosciences Limited’s upcoming earnings report date is Mar 19, 2027 which is in 201 days.

How were Brii Biosciences Limited’s earnings last quarter?

Brii Biosciences Limited released its earnings results on Aug 20, 2026. The company reported -HK$0.163 earnings per share for the quarter, missing the consensus estimate of -HK$0.128 by -HK$0.035.

Is Brii Biosciences Limited overvalued?

According to Wall Street analysts Brii Biosciences Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Brii Biosciences Limited pay dividends?

Brii Biosciences Limited does not currently pay dividends.

What is Brii Biosciences Limited’s EPS estimate?

Brii Biosciences Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Brii Biosciences Limited have?

Brii Biosciences Limited has 734,958,250 shares outstanding.

What happened to Brii Biosciences Limited’s price movement after its last earnings report?

Brii Biosciences Limited reported an EPS of -HK$0.163 in its last earnings report, missing expectations of -HK$0.128. Following the earnings report the stock price went up 3.571%.

Which hedge fund is a major shareholder of Brii Biosciences Limited?

Currently, no hedge funds are holding shares in HK:2137

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Brii Biosciences Limited

Founded in Beijing, China, in 2017, Brii Biosciences Limited is a biopharmaceutical firm dedicated to discovering and developing innovative therapies for infectious diseases and central nervous system disorders. Its diverse pipeline features: early-stage (Phase 1) compounds BRII-778 and BRII-732 for treating HIV; a multifaceted approach to Hepatitis B (HBV) including a Phase 2 combination study of BRII-179 and BRII-835, with BRII-179 (a recombinant protein-based immunotherapeutic) also in Phase 1b/2a, and BRII-835 having successfully completed Phase 2 for chronic HBV patients. The company also offers the Amubarvimab/romlusevimab combination as a treatment for COVID-19. Beyond these, Brii Biosciences is advancing BRII-296 for PPD and BRII-297 for various depressive conditions, alongside several agents targeting highly resistant infections: BRII-636, BRII-672, and BRII-693 are designed to combat multi-drug and extensively drug-resistant (MDR/XDR) gram-negative bacteria, while BRII-658 is under development for MDR/XDR tuberculosis and non-tuberculosis mycobacterial infections.